🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 61 of 757 · Phase 3 first, then by program name

  1. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Infantile Spasms

    phase 3 small molecule completed

    2 trials

  2. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    3 trials

  3. Ga-68-PSMA-11

    Telix Innovations

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  4. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Dependence

    phase 3 small molecule completed

    1 trial

  5. Gabapentin 300mg

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Drinking

    phase 3 small molecule completed

    1 trial

  6. Gabitril

    Teva Pharma GmbH

    Anxiety Disorders

    phase 3 small molecule completed

    1 trial

  7. Gabitril

    Teva Pharma GmbH

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    2 trials

  8. Gabitril

    Teva Pharma GmbH

    Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  9. Galantamine

    INTEGRATED BIOPHARMA INC

    Acute Ischemic Stroke AIS

    phase 3 small molecule active

    1 trial

  10. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  11. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  12. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  13. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  14. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed), SODIUM CHLORIDE

    Pari Pharma GmbH

    External Genital Warts (EGW)

    phase 3 small molecule active

    1 trial

  15. Gardasill 9™ vaccine

    United Therapeutics Europe Ltd

    Neoplasia

    phase 3 mab completed

    1 trial

  16. Garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  17. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Roche Registration Limited

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  18. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Pharma Mar S.A.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  19. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Roche Registration Limited

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  20. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Roche Registration Limited

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  22. Gefarnate

    First Tracks Biotherapeutics

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  23. Gefitinib

    China SXT Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources